Singapore, Dec. 16 -- US-based ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer's disease and related dementias, has announced a licensing agreement withSiemens Healthineersfor use of its proprietary pTau217 antibody in the development of a pTau217 assay in the expanding menu of Siemens Healthineersin vitrodiagnostic (IVD) tests for Alzheimer's disease.The test is being designed for use on Siemens Healthineers' Atellica immunoassay systems.

Blood-based neurodegenerative disease diagnostics, including those for Alzheimer's, are a transformative advancement. The ALZpath pTau217 antibody has shown exceptional performance across a range of platforms to help identify patients with Alzheimer's disease through a s...